P14.21 Tehila Kaisman-Elbaz MD/PhD

P14.21 Tehila Kaisman-Elbaz MD/PhD

Abstract BACKGROUND Glioblastoma is known for its dismal prognosis though its dependency on patients’ readily available RBCs parameters defining the patient’s anemic status such as hemoglobin level and Red blood cells distribution Width (RDW) is not fully established. Several works demonstrated a co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2019-09, Vol.21 (Supplement_3), p.iii71-iii71
Hauptverfasser: Kaisman-Elbaz, T, Elbaz, Y, Merkin, V, Dym, L, Noy, A, Atar-Vardi, M, Bari, R, Turiel, S, Lavrenkov, K, Melamed, I
Format: Artikel
Sprache:eng
Schlagworte:
Poster Presentations
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page iii71
container_issue Supplement_3
container_start_page iii71
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 21
creator Kaisman-Elbaz, T
Elbaz, Y
Merkin, V
Dym, L
Noy, A
Atar-Vardi, M
Bari, R
Turiel, S
Lavrenkov, K
Melamed, I
description Abstract BACKGROUND Glioblastoma is known for its dismal prognosis though its dependency on patients’ readily available RBCs parameters defining the patient’s anemic status such as hemoglobin level and Red blood cells distribution Width (RDW) is not fully established. Several works demonstrated a connection between low hemoglobin level or high RDW values to overall glioblastoma patient’s survival, but in other works, a clear connection was not found. This study addresses this unclarity. MATERIAL AND METHODS In this work, 170 glioblastoma patients, diagnosed and treated in Soroka University Medical Center (SUMC) in the last 12 years were retrospectively inspected for their survival dependency on pre-operative RBCs parameters using multivariate analysis followed by false discovery rate procedure due to the multiple hypothesis testing. A survival stratification tree and Kaplan-Meier survival curves that indicate the patient’s prognosis according to these parameters were prepared. RESULTS Beside KPS>70 and tumor resection supplemented by oncological treatment, age
doi_str_mv 10.1093/neuonc/noz126.256
format Article
fullrecord <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6795936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noz126.256</oup_id><sourcerecordid>10.1093/neuonc/noz126.256</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1776-8b825151f5c07cdb2d227863525282a5ea45a1c67d26ffbabf2b2477b211f0b73</originalsourceid><addsrcrecordid>eNqNkE1Lw0AQQBdRsFZ_gLfi2U13Jp3d5CJIWz-wYg_1vOxudk0kHyWxgv31RiOCN08zMPPe4TF2DiICkcbT2u-a2k3rZg8oIyR5wEZAGHNKpDz83pEnBOqYnXTdqxAIJGHELtYwixAmG58XpZk8mKKrTM2XpTX7yeNius4Xp-womLLzZz9zzJ5vlpv5HV893d7Pr1fcgVKSJzZBAoJATiiXWcwQVSJjQsIEDXkzIwNOqgxlCNbYgBZnSlkECMKqeMyuBu92ZyufOV-_tabU27aoTPuhG1Pov5e6yPVL866lSimNZS-AQeDaputaH35ZEPqrkh4q6aGS7iv1zOXANLvtP94_AQkXaqE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P14.21 Tehila Kaisman-Elbaz MD/PhD</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kaisman-Elbaz, T ; Elbaz, Y ; Merkin, V ; Dym, L ; Noy, A ; Atar-Vardi, M ; Bari, R ; Turiel, S ; Lavrenkov, K ; Melamed, I</creator><creatorcontrib>Kaisman-Elbaz, T ; Elbaz, Y ; Merkin, V ; Dym, L ; Noy, A ; Atar-Vardi, M ; Bari, R ; Turiel, S ; Lavrenkov, K ; Melamed, I</creatorcontrib><description>Abstract BACKGROUND Glioblastoma is known for its dismal prognosis though its dependency on patients’ readily available RBCs parameters defining the patient’s anemic status such as hemoglobin level and Red blood cells distribution Width (RDW) is not fully established. Several works demonstrated a connection between low hemoglobin level or high RDW values to overall glioblastoma patient’s survival, but in other works, a clear connection was not found. This study addresses this unclarity. MATERIAL AND METHODS In this work, 170 glioblastoma patients, diagnosed and treated in Soroka University Medical Center (SUMC) in the last 12 years were retrospectively inspected for their survival dependency on pre-operative RBCs parameters using multivariate analysis followed by false discovery rate procedure due to the multiple hypothesis testing. A survival stratification tree and Kaplan-Meier survival curves that indicate the patient’s prognosis according to these parameters were prepared. RESULTS Beside KPS&gt;70 and tumor resection supplemented by oncological treatment, age&lt;70 (HR=0.4, 95% CI 0.24–0.65), low hemoglobin level (HR=1.79, 95% CI 1.06–2.99) and RDW&lt;14% (HR=0.57, 95% CI 0.37–0.88) were found to be prognostic to patients’ overall survival in multivariate analysis, accounting for false discovery rate of less than 5%. CONCLUSION A survival stratification highlighted a non-anemic subgroup of nearly 30% of the cohort’s patients whose median overall survival was 21.1 months (95% CI 16.2–27.2) - higher than the average Stupp protocol overall median survival of about 15 months. A discussion on the beneficial or detrimental effect of RBCs parameters on glioblastoma prognosis and its possible causes is given.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noz126.256</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Poster Presentations</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2019-09, Vol.21 (Supplement_3), p.iii71-iii71</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795936/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795936/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1583,27923,27924,53790,53792</link.rule.ids></links><search><creatorcontrib>Kaisman-Elbaz, T</creatorcontrib><creatorcontrib>Elbaz, Y</creatorcontrib><creatorcontrib>Merkin, V</creatorcontrib><creatorcontrib>Dym, L</creatorcontrib><creatorcontrib>Noy, A</creatorcontrib><creatorcontrib>Atar-Vardi, M</creatorcontrib><creatorcontrib>Bari, R</creatorcontrib><creatorcontrib>Turiel, S</creatorcontrib><creatorcontrib>Lavrenkov, K</creatorcontrib><creatorcontrib>Melamed, I</creatorcontrib><title>P14.21 Tehila Kaisman-Elbaz MD/PhD</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract BACKGROUND Glioblastoma is known for its dismal prognosis though its dependency on patients’ readily available RBCs parameters defining the patient’s anemic status such as hemoglobin level and Red blood cells distribution Width (RDW) is not fully established. Several works demonstrated a connection between low hemoglobin level or high RDW values to overall glioblastoma patient’s survival, but in other works, a clear connection was not found. This study addresses this unclarity. MATERIAL AND METHODS In this work, 170 glioblastoma patients, diagnosed and treated in Soroka University Medical Center (SUMC) in the last 12 years were retrospectively inspected for their survival dependency on pre-operative RBCs parameters using multivariate analysis followed by false discovery rate procedure due to the multiple hypothesis testing. A survival stratification tree and Kaplan-Meier survival curves that indicate the patient’s prognosis according to these parameters were prepared. RESULTS Beside KPS&gt;70 and tumor resection supplemented by oncological treatment, age&lt;70 (HR=0.4, 95% CI 0.24–0.65), low hemoglobin level (HR=1.79, 95% CI 1.06–2.99) and RDW&lt;14% (HR=0.57, 95% CI 0.37–0.88) were found to be prognostic to patients’ overall survival in multivariate analysis, accounting for false discovery rate of less than 5%. CONCLUSION A survival stratification highlighted a non-anemic subgroup of nearly 30% of the cohort’s patients whose median overall survival was 21.1 months (95% CI 16.2–27.2) - higher than the average Stupp protocol overall median survival of about 15 months. A discussion on the beneficial or detrimental effect of RBCs parameters on glioblastoma prognosis and its possible causes is given.</description><subject>Poster Presentations</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNkE1Lw0AQQBdRsFZ_gLfi2U13Jp3d5CJIWz-wYg_1vOxudk0kHyWxgv31RiOCN08zMPPe4TF2DiICkcbT2u-a2k3rZg8oIyR5wEZAGHNKpDz83pEnBOqYnXTdqxAIJGHELtYwixAmG58XpZk8mKKrTM2XpTX7yeNius4Xp-womLLzZz9zzJ5vlpv5HV893d7Pr1fcgVKSJzZBAoJATiiXWcwQVSJjQsIEDXkzIwNOqgxlCNbYgBZnSlkECMKqeMyuBu92ZyufOV-_tabU27aoTPuhG1Pov5e6yPVL866lSimNZS-AQeDaputaH35ZEPqrkh4q6aGS7iv1zOXANLvtP94_AQkXaqE</recordid><startdate>20190906</startdate><enddate>20190906</enddate><creator>Kaisman-Elbaz, T</creator><creator>Elbaz, Y</creator><creator>Merkin, V</creator><creator>Dym, L</creator><creator>Noy, A</creator><creator>Atar-Vardi, M</creator><creator>Bari, R</creator><creator>Turiel, S</creator><creator>Lavrenkov, K</creator><creator>Melamed, I</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20190906</creationdate><title>P14.21 Tehila Kaisman-Elbaz MD/PhD</title><author>Kaisman-Elbaz, T ; Elbaz, Y ; Merkin, V ; Dym, L ; Noy, A ; Atar-Vardi, M ; Bari, R ; Turiel, S ; Lavrenkov, K ; Melamed, I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1776-8b825151f5c07cdb2d227863525282a5ea45a1c67d26ffbabf2b2477b211f0b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Poster Presentations</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaisman-Elbaz, T</creatorcontrib><creatorcontrib>Elbaz, Y</creatorcontrib><creatorcontrib>Merkin, V</creatorcontrib><creatorcontrib>Dym, L</creatorcontrib><creatorcontrib>Noy, A</creatorcontrib><creatorcontrib>Atar-Vardi, M</creatorcontrib><creatorcontrib>Bari, R</creatorcontrib><creatorcontrib>Turiel, S</creatorcontrib><creatorcontrib>Lavrenkov, K</creatorcontrib><creatorcontrib>Melamed, I</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaisman-Elbaz, T</au><au>Elbaz, Y</au><au>Merkin, V</au><au>Dym, L</au><au>Noy, A</au><au>Atar-Vardi, M</au><au>Bari, R</au><au>Turiel, S</au><au>Lavrenkov, K</au><au>Melamed, I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P14.21 Tehila Kaisman-Elbaz MD/PhD</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2019-09-06</date><risdate>2019</risdate><volume>21</volume><issue>Supplement_3</issue><spage>iii71</spage><epage>iii71</epage><pages>iii71-iii71</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract BACKGROUND Glioblastoma is known for its dismal prognosis though its dependency on patients’ readily available RBCs parameters defining the patient’s anemic status such as hemoglobin level and Red blood cells distribution Width (RDW) is not fully established. Several works demonstrated a connection between low hemoglobin level or high RDW values to overall glioblastoma patient’s survival, but in other works, a clear connection was not found. This study addresses this unclarity. MATERIAL AND METHODS In this work, 170 glioblastoma patients, diagnosed and treated in Soroka University Medical Center (SUMC) in the last 12 years were retrospectively inspected for their survival dependency on pre-operative RBCs parameters using multivariate analysis followed by false discovery rate procedure due to the multiple hypothesis testing. A survival stratification tree and Kaplan-Meier survival curves that indicate the patient’s prognosis according to these parameters were prepared. RESULTS Beside KPS&gt;70 and tumor resection supplemented by oncological treatment, age&lt;70 (HR=0.4, 95% CI 0.24–0.65), low hemoglobin level (HR=1.79, 95% CI 1.06–2.99) and RDW&lt;14% (HR=0.57, 95% CI 0.37–0.88) were found to be prognostic to patients’ overall survival in multivariate analysis, accounting for false discovery rate of less than 5%. CONCLUSION A survival stratification highlighted a non-anemic subgroup of nearly 30% of the cohort’s patients whose median overall survival was 21.1 months (95% CI 16.2–27.2) - higher than the average Stupp protocol overall median survival of about 15 months. A discussion on the beneficial or detrimental effect of RBCs parameters on glioblastoma prognosis and its possible causes is given.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noz126.256</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2019-09, Vol.21 (Supplement_3), p.iii71-iii71
issn 1522-8517
1523-5866
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6795936
source Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Poster Presentations
title P14.21 Tehila Kaisman-Elbaz MD/PhD
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T14%3A10%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P14.21%20Tehila%20Kaisman-Elbaz%20MD/PhD&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Kaisman-Elbaz,%20T&rft.date=2019-09-06&rft.volume=21&rft.issue=Supplement_3&rft.spage=iii71&rft.epage=iii71&rft.pages=iii71-iii71&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noz126.256&rft_dat=%3Coup_pubme%3E10.1093/neuonc/noz126.256%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noz126.256&rfr_iscdi=true